Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

301
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
301
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

389
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
389
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

241
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
241
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

185
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
185
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

265
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
265
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

174
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual Prognosis Following Cataract Surgery in Highly Myopic Patients with Prior History of Verisyse Phakic Intraocular Lens Implantation.

Journal of clinical medicine·2024
Same author

Visual Outcomes of Cataract Surgery in Patients with Previous History of Implantable Collamer Lens.

Journal of clinical medicine·2024
Same author

Postinfarction Ventricular Septal Ruptures During the COVID-19 Pandemic: Two Case Series.

Cureus·2023
Same author

A Rare Case of Pertuzumab-Induced Toxic Epidermal Necrolysis.

Cureus·2023
Same author

Sickle Cell Anemia Associated With Increased In-Hospital Mortality in Post-Cardiac Arrest Patients.

Cureus·2023
Same author

Anaplastic Large-Cell Lymphoma (ALCL) First Manifested as a Rapidly Progressive Acute Respiratory Failure (RF): Lymph Node Biopsy Negative Presentation Posing a Diagnostic Challenge.

Cureus·2023

Related Experiment Video

Updated: Aug 6, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K

Sevoflurane-Induced Diffuse Alveolar Hemorrhage.

Mohammad Ahmed-Khan1, Kayvon Moin2, Carly Funk2

  • 1Danbury Hospital-Yale University, School of Medicine, Danbury, Netherlands Antilles.

Archive of Clinical Cases
|March 17, 2023
PubMed
Summary

Diffuse alveolar hemorrhage (DAH), a serious lung condition, can be caused by sevoflurane, an anesthetic. This case highlights the importance of considering sevoflurane as a potential cause of DAH in postoperative patients presenting with respiratory distress.

Keywords:
AnesthesiaCritical CareDiffuse Alveolar HemorrhageRespiratory DistressSevoflurane

More Related Videos

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
04:56

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

Published on: October 23, 2018

6.7K
Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
03:02

Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification

Published on: July 25, 2025

24

Related Experiment Videos

Last Updated: Aug 6, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.8K
In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
04:56

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

Published on: October 23, 2018

6.7K
Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification
03:02

Application of Dixon's Up-and-Down Design to Estimate the Minimum Alveolar Concentration of Sevoflurane in Rats with Refined Movement Classification

Published on: July 25, 2025

24

Area of Science:

  • Pulmonary Medicine
  • Anesthesiology
  • Critical Care

Background:

  • Diffuse alveolar hemorrhage (DAH) is a critical pulmonary condition characterized by bleeding into the lung's alveoli.
  • It typically presents with hemoptysis, hypoxemia, and pulmonary infiltrates, often due to alveolar capillary basement membrane disruption.

Observation:

  • A rare case of postoperative DAH in a young, healthy male is presented.
  • The condition was linked to sevoflurane, a commonly used inhalational anesthetic agent.

Findings:

  • This report adds to the limited literature, with only five prior documented cases of sevoflurane-induced DAH.
  • A temporal relationship between sevoflurane administration and the onset of DAH symptoms was observed.

Implications:

  • Sevoflurane should be considered a potential etiological factor for DAH in postoperative patients exhibiting respiratory distress and hemoptysis.
  • Increased awareness may improve diagnosis and management of this rare but severe anesthetic complication.